MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -932 Million JPY | 16.12% |
| 2022 | -1.11 Billion JPY | -4.84% |
| 2021 | -1.05 Billion JPY | 4.92% |
| 2020 | -1.11 Billion JPY | 31.04% |
| 2019 | -1.61 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 67.26 Million JPY | 152.44% |
| 2024 Q1 | -128.27 Million JPY | 50.97% |
| 2023 Q4 | -261.61 Million JPY | -38.18% |
| 2023 FY | -932 Million JPY | 16.12% |
| 2023 Q3 | -189.32 Million JPY | 1.11% |
| 2023 Q2 | -191.44 Million JPY | 34.1% |
| 2023 Q1 | -290.5 Million JPY | 38.96% |
| 2022 Q4 | -475.95 Million JPY | -87.34% |
| 2022 FY | -1.11 Billion JPY | -4.84% |
| 2022 Q3 | -254.06 Million JPY | 0.0% |
| 2021 FY | -1.05 Billion JPY | 4.92% |
| 2020 FY | -1.11 Billion JPY | 31.04% |
| 2019 FY | -1.61 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 129.08% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 100.647% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 99.704% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 100.575% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | 955.368% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 103.605% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 111.614% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 102.198% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | 233.716% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 106.672% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 120.497% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 167.683% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | -417.778% |
| Tsumura & Co. | 16.7 Billion JPY | 105.579% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 108.351% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 122.627% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 105.763% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 127.132% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 112.055% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 117.512% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 80.956% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 128.285% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | 52.517% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 124.694% |
| Solasia Pharma K.K. | -1.11 Billion JPY | 16.187% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | 61.034% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 112.353% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 106.805% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | -58.178% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 104.512% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 131.632% |